We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05384470
Recruitment Status : Recruiting
First Posted : May 20, 2022
Last Update Posted : June 24, 2022
Information provided by (Responsible Party):
Scott Lukas, Mclean Hospital

Brief Summary:
This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.

Condition or disease Intervention/treatment Phase
Opiate Abuse Marijuana Abuse Drug: Marihuana Device: BID2 Instrument - breathalyzer Phase 2

Detailed Description:

This study is intended to lead to the development and demonstration of a breathalyzer instrument capable of detecting and quantitatively measuring drugs (i.e. cannabinoids and opioids) in exhaled breath (EB). Prior work on the detection of these drugs in EB by means of liquid chromatography and mass spectrometry (LC/MS) demonstrated that these compounds can be quantitatively detected, but LC/MS is slow, expensive and requires highly skilled personnel to implement. What is needed is a simple and inexpensive method for rapidly measuring the amount of drugs in EB.

If such a method becomes available it can be used by law enforcement and in doctors' offices, hospital emergency rooms, ambulances and other government agencies, military bases and companies seeking to screen employees for drug abuse. Vox Biomedical proposes to develop a method for quantitatively detecting the presence of drugs in EB by means of Differential Mobility Spectrometry (DMS) developed at Draper Laboratories. DMS is a robust, datarich, ultra-trace, chemical detection technology that has been proven for numerous applications including air quality cabin monitoring on the International Space Station (ISS), chemical warfare agent detection, explosives detection, and drinking water analysis. Recently Draper has applied this device to breath analysis for the detection of lung diseases.

A clinical study is currently underway and initial results are promising. This project involves transferring this technology developed by Draper for lung infection detection to the detection of psychoactive drugs in exhaled breath. Phase I of the proposed program will investigate the DMS signatures of cannabinoids in the laboratory and defining the device's limits of detection. A small pilot study will also be performed to demonstrate feasibility for using breath analysis as a proxy for the concentration of cannabinoids in the blood.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
Actual Study Start Date : July 1, 2021
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Arm Intervention/treatment
Exhaled Breath Samples
Quantitative detection of marijuana, morphine or fentanyl through exhaled breath
Drug: Marihuana
Two doses of marijuana given.

Device: BID2 Instrument - breathalyzer
The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.

Primary Outcome Measures :
  1. Breath/cannabinoids concentrations [ Time Frame: 1 year ]
    Quantitatively measuring cannabinoids in exhaled breath

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Capable of understanding and complying with the protocol
  • In good physical and mental health (normal physical exam, ECG, blood and urine chemistries
  • Absence of history or laboratory evidence of diabetes)
  • Body Mass Index between 18-30,
  • Inclusive Age 21-50 years (age will be verified by driver's license or other valid form of identification)
  • Have a stable living situation with current postal address.

Exclusion criteria

  • Meets criteria for current alcohol or substance use disorders (Past alcohol or substance use disorders greater than 3 years ago is acceptable)
  • Concurrent diagnosis of Axis 1 disorder be maintained on an antipsychotic or antidepressant medication
  • Taking prescription medications except certain short-term anti-fungal agents and some topical creams for dermal condition
  • Heavy alcohol drinkers (greater than 15 drinks per week)
  • Tobacco use greater than 5 cigarettes per day
  • History of major head trauma resulting in cognitive impairment or history of seizure disorder
  • Heavy caffeine use (greater than 500 mg on a regular daily basis)
  • Has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT)> 3x the upper limit of normal
  • For female participants, a positive pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05384470

Layout table for location contacts
Contact: Scott E. Lukas, Ph.D. 617-855-2767 slukas@mclean.harvard.edu

Layout table for location information
United States, Massachusetts
McLean Hospital Recruiting
Belmont, Massachusetts, United States, 02478
Contact: Scott Lukas, Ph.D.    617-855-2767    slukas@mclean.harvard.edu   
Sponsors and Collaborators
Mclean Hospital
Layout table for additonal information
Responsible Party: Scott Lukas, Director, McLean Imaging Center and BPRL, Mclean Hospital
ClinicalTrials.gov Identifier: NCT05384470    
Other Study ID Numbers: 2019P001633
5R42DA049655-04 ( U.S. NIH Grant/Contract )
First Posted: May 20, 2022    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Narcotic-Related Disorders